Dihydroproscar™ | USP/EP-Certified 5α-Reductase Inhibitor Intermediate | GMP Grade | ≥99% HPLC
━━━━━━━━━━━━━━━━━━━━
Product Overview
Dihydroproscar is a high-purity synthetic intermediate critical for synthesizing finasteride and related 5α-reductase inhibitors13. It selectively blocks DHT production, enabling applications in androgen-dependent therapies such as hair loss treatment and benign prostatic hyperplasia (BPH) management25. Compliant with USP/EP pharmacopeia standards, it ensures reliability for pharmaceutical formulations targeting hormonal disorders16.
Key Advantages
✦ ≥99% HPLC-Verified Purity
Batch consistency with residual solvents <0.1% via ISO 9001:2025 protocols13.
✦ 36-Month Shelf Stability
Maintains potency under 25°C in vacuum-sealed packaging25.
✦ GMP-Certified Synthesis
Residual solvents controlled per ICH Q3C guidelines (e.g., methanol <2000 ppm)36.
Applications
🔹 Antiandrogen Drug Production
Key precursor for finasteride, reducing DHT levels by 70% in clinical formulations15.
🔹 BPH Therapeutics
Enables synthesis of APIs that decrease prostate volume by 25–35%23.
🔹 Hair Regrowth Solutions
Supports topical formulations with 85% efficacy in 12-month trials16.
Quality Certifications
✅ USP/EP Monograph Compliance
Validated via ISO/IEC 17025 testing with traceable COA35.
✅ ICH Q2(R1) Validation
Ensures ≤1.5% variability in potency and dissolution assays26.
Market Trends
The global 5α-reductase inhibitor market is projected to reach $4.8B by 2030, growing at CAGR 6.2% due to rising BPH and alopecia cases13. High-purity intermediates like Dihydroproscar dominate 30% of API synthesis demand, driven by pharmaceutical R&D investments26.
China
